Premium
Vitamin K status in cystic fibrosis
Author(s) -
Cornelissen EAM,
Lieburg AF,
Motohara K,
Oostrom CG
Publication year - 1992
Publication title -
acta pædiatrica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.772
H-Index - 115
eISSN - 1651-2227
pISSN - 0803-5253
DOI - 10.1111/j.1651-2227.1992.tb12327.x
Subject(s) - cystic fibrosis , medicine , vitamin , vitamin k deficiency , vitamin k , endocrinology , prothrombin time , gastroenterology
Appearance of PIVKA‐II (protein induced by vitamin K absence‐II) in serum is a biochemical sign of insufficient vitamin K‐dependent carboxylation of prothrombin. Plasma concentrations of PIVKA‐II and vitamin K 1 , were determined in 24 children with cystic fibrosis. Eight were supplemented with vitamin K 1 . The purpose of the study was to determine the occurrence of vitamin K deficiency in cystic fibrosis and to evaluate the effect of vitamin K supplementation. PIVKA‐II was detectable in only one unsupplemented child. In this patient, the concentration of vitamin K 1 was below the limit of detection of 60 ng/l. Vitamin K 1 levels in the other unsupplemented children were normal (mean 476 ng/l= 1 mmol/l). The supplemented patients showed extremely high levels of vitamin K 1 (mean 22 445 ng/l = 50 nmol/l). In conclusion, vitamin K deficiency occurs infrequently in cystic fibrosis. Checking the coagulation system is advised, but routine vitamin K supplementation is not recommended. If additional vitamin K is needed, the starting dose should not exceed 1 mg daily.